title: Local control after tailored surgical treatment of early cervical cancer.
abstract: BACKGROUND
  It was the aim of our study to analyze oncological outcome and prognostic parameters in patients with early stages cervical cancer after tailored and well-standardized surgical treatment with an adequate follow-up.
  
  
  METHODS
  Oncological outcome and prognostic parameters were evaluated in a group of 192 patients with cervical cancer stages IA2 to 2B who had undergone radical hysterectomy (n = 171), radical parametrectomy (n = 12), or radical trachelectomy (n = 9). Procedures were classified as type B (n = 72), type C1 nerve sparing (n = 103), or type C2 (n = 17).
  
  
  RESULTS
  Event-free and overall 5-year survivals probabilities reached 92.7% (confidence interval, 89.5%-95.9 %) and 94.1% (confidence interval, 90.9%-97.3 %). There was only 1 isolated pelvic recurrence found of the total of 10 recurrences. Adjuvant radiotherapy was given to only 22% of patients. The most significant independent prognostic parameters in stage IB tumors were lymph node status, histological type, and tumor volume, whereas in stage II, the parameters included histological type and tumor volume, the latter being inversely related to the prognosis.
  
  
  CONCLUSIONS
  We have shown an excellent prognosis, especially local control, after tailored surgical treatment of stages IA2 to IIB of cervical cancer, with low prevalence of adjuvant treatment. Different prognostic parameters were observed for stages IB1/IB2 and IIA/B.
authors.affiliation: Gynecological Oncology Centre, Department of Obstetrics and Gynecology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. david.cibula@iol.cz
authors.forename: David
authors.initials: D
authors.lastname: Cibula
authors.forename: Ivana
authors.initials: I
authors.lastname: Pinkavova
authors.forename: Ladislav
authors.initials: L
authors.lastname: Dusek
authors.forename: Jiri
authors.initials: J
authors.lastname: Slama
authors.forename: Michael
authors.initials: M
authors.lastname: Zikan
authors.forename: Daniela
authors.initials: D
authors.lastname: Fischerova
authors.forename: Pavel
authors.initials: P
authors.lastname: Freitag
authors.forename: Pavel
authors.initials: P
authors.lastname: Dundr
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant / Q000706:statistics & numerical data; D018450:Disease Progression; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D018714:Radiotherapy, Adjuvant / Q000706:statistics & numerical data; D020266:Radiotherapy, Conformal; D012189:Retrospective Studies; D016019:Survival Analysis; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*